Skip to main content Skip to main navigation menu Skip to site footer

Effect Sacubitril/Valsartan in patients with Acute Myocardial Infarction (AMI): a systematic review and meta-analysis



Abstract

Background: Acute Myocardial Infarction (AMI) is a type of coronary heart disease with high morbidity and mortality. The renin-angiotensin-aldosterone system (RAAS) is an important endocrine system in controlling blood pressure and cardiovascular homeostasis and is responsible for AMI. In patients with AMI or a heart attack, sacubitril/valsartan has been shown to reduce the risk of heart failure and death. This study aims to evaluate the effect of sacubitril/valsartan in AMI patients.

Methods: In order to evaluate the effects of sacubitril/valsartan in patients with AMI, three databases, including PubMed, Cochrane Library, and the ClinicalTrials website, were searched. The final search was performed in January 2023. The meta‑analysis was subsequently performed with Revman 5.4 software and a total of three studies were included.

Results: The results of the main outcomes showed that sacubitril/valsartan has no significant reduction in major adverse cardiovascular and cerebrovascular events (MACCEs) odds ratio (OR), 0.70; 95% confidence interval (CI), 0.38‑1.30; P=0.26] and incidence of acute heart failure (AHF) (OR, 0.52; 95% CI, 0.24‑1.15; P=0.11). The secondary outcomes showed no effect of sacubitril/valsartan to increase left ventricular remodeling.

Conclusion: In conclusion, the present meta‑analysis revealed that sacubitril/valsartan could not effectively reduce the incidence of MACCEs and AHF in patients with AMI. In the future, a meta‑analysis study will be designed with many studies to reduce the incidence of MACCEs and AHF effectively.

Keywords: Sacubitril Valsartan AMI MACCEs

References

  1. Kaul P, Ezekowitz JA, Armstrong PW, Leung BK, Savu A, Welsh RC, et al. Incidence of heart failure and mortality after acute coronary syndromes. Am Heart J. 2013;165(3):379-85.e2.
  2. Amrullah S, Rosjidi CH, Dhesa DB, Wurjatmiko AT, Hasrima. Faktor Resiko Penyakit Infark Miokard Akut di Rumah Sakit Umum Dewi Sartika Kota Kendari. Jurnal Ilmiah Karya Kesehatan. 2022;2(2):21-29.
  3. Yang P, Han Y, Lian C, Wu X. Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis. Front Cardiovasc Med. 2022;9:988117. Published 2022 Aug 24. doi:10.3389/fcvm.2022.988117
  4. Dargie HJ, Byrne J. Pathophysiological Aspects of The Renin-Angiotensin-Aldosterone System in Acute Myocardial Infarction. J Cardiovasc Risk. 1995;2(5):389-95.
  5. Cherub J. Tinjauan atas Angiotensin Receptor Blocker Generasi Baru. Cermin Dunia Kedokteran. 2020;47(8):715-718.
  6. Amin OA, Alaarag AF. The impact of discontinuation of sacubitril-valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction. Anatol J Cardiol. 2021;25(3):163-169. doi:10.14744/AnatolJCardiol.2020.39267
  7. She J, Lou B, Liu H, Zhou B, Jiang GT, Luo Y, et al. ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction. ESC Heart Fail. 2021;8(6):4607-4616.
  8. Xiong B, Nie D, Qian J, Yao Y, Yang G, Rong S, et al. The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis. ESC Heart Fail. 2021;8(6):4852-4862.
  9. Rezq A, Saad M, El Nozahi M. Sacubitril/valsartan versus ramipril in patients with ST-segment Elevation Myocardial Infarction and cardiogenic SHOCK (SAVE-SHOCK): a pilot randomized controlled trial. Am J Cardiovasc Dis. 2021;11(6):734-742.
  10. Dong Y, Xu Y, Ding C, Yu Z, Yu Z, Xia X, et al. Comparing the efficacy of angiotensin receptor-neprilysin inhibitor and enalapril in acute anterior STEMI patients after primary percutaneous coronary intervention: a prospective randomized trial. Cardiovasc Diagn Ther. 2022;12(1):42-54.
  11. Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, et al. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation. 2022;145(1):87-89.
  12. Liu S, Yin B, Wu B, Fan Z. Protective effect of sacubitril/valsartan in patients with acute myocardial infarction: A meta-analysis. Exp Ther Med. 2022;23(6):406.
  13. Zhao J, Zeng Y, Shen X. Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A meta-analysis. Clin Cardiol. 2021;44(10):1354-1359.
  14. Liu S, Yin B, Wu B, Fan Z. Protective effect of sacubitril/valsartan in patients with acute myocardial infarction: A meta-analysis. Exp Ther Med. 2022;23(6):406.
  15. Zhao J, Zeng Y, Shen X. Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A meta-analysis. Clin Cardiol. 2021;44(10):1354-1359.
  16. Tsutsui H, Momomura S, Saito Y, Ito H, Yamamoto K, Ohishi T, et al. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. J Cardiol. 2017;70(3):225-231.
  17. Yosaputra C, Lefrandt RP, Panda AL, Pangemanan J. Correlation between Left Ventricular Ejection Fraction (LVEF) and six-month mortality risks after hospital discharge following myocardial infarction in patients with Non-ST-Elevation Myocardial Infarction (NSTEMI) at Prof. Dr. R. D. Kandou General Hospital, Manado, Indonesia. Bali Medical Journal. 2021;10(3):975-978.
  18. Panda AL, Polii NCI, Rooroh VGX, Haurissa AE, Sarayar AM, Yofrido FM. Correlation between short-term heart rate variability and QT-Interval with left ventricular systolic function in patients with stable Coronary Artery Disease (CAD): a cross-sectional study. Bali Medical Journal. 2021;10(3):1026-1030.
  19. Rampengan SH, Posangi J, Tallei T, Immanuel S, Lolombulan J, Prihartono J. Association of Helicobacter pylori and left ventricular ejection fraction in patients with acute myocardial infarction. Bali Medical Journal. 2016;5(3):556-561.

How to Cite

Pratistha, F. S. M., & Ardiana, I. W. S. (2023). Effect Sacubitril/Valsartan in patients with Acute Myocardial Infarction (AMI): a systematic review and meta-analysis. Intisari Sains Medis, 14(2), 621–625. https://doi.org/10.15562/ism.v14i2.1723
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
0

Total
0

Share

Search Panel

Fernanda Savitri Mega Pratistha
Google Scholar
Pubmed
ISM Journal

I Wayan Surya Ardiana
Google Scholar
Pubmed
ISM Journal